RXMD Well that's why they pride themselves for not being the typical pharmacy. Their MTM revenue grew 50% so they have always been ahead of the curve as far as diversifying.
Now, in terms of flat line scripts that's not necessarily an abnormal thing.
I do agree that a second location is what's next for them.
So that's a second location and M&A which would be unreal in terms of catalysts.